Search
Cefminox
go.drugbank.com/drugs/DB09062ExperimentalCefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseISS-1018
go.drugbank.com/drugs/DB05463InvestigationalISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. … ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity.
Technetium Tc-99m tilmanocept
go.drugbank.com/drugs/DB09266ApprovedTechnetium Tc-99m tilmanocept is a radiopharmaceutical diagnostic imaging agent approved by the U.S. … Detecting sentinel lymph node (SLN) is clinically useful in the prognosis and management of the disease, as it is considered as the first lymph node that receives afferent lymphatic drainage from a primary
Ofloxacin
go.drugbank.com/drugs/DB01165ApprovedInvestigationalA synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … when compared to [crizotinib].
Guanidine
go.drugbank.com/drugs/DB00536ApprovedIt is also used in laboratory research as a protein denaturant. … A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism.
Rilapladib
go.drugbank.com/drugs/DB05119InvestigationalIt is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques. … Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development.
Everolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIt is currently used as an immunosuppressant to prevent rejection of organ transplants. … Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor.